HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Top Medical News

Mirtazapine and Carbamazepine Fail to Demonstrate Clinical and Cost Effectiveness as Alzheimer Agitation Treatments

December 03, 2022

By Marco Meglio

Over a 12-week treatment period, investigators found no significant differences in mean Cohen Mansfield Agitation Inventory scores between mirtazapine and placebo, with similar rates in adverse events.

NeurologyLive® Friday 5 — December 2, 2022

December 02, 2022

By NeurologyLive® Staff

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 2, 2022.

Brexpiprazole Continues to Demonstrate Efficacy as Alzheimer Agitation Therapy Across Multiple Phase 3 Trials

December 02, 2022

By Marco Meglio

Across 3 trials in patients with Alzheimer disease agitation, brexpiprazole doses of 2 or 3 mg/day was safe and showed a statistically significant improvement vs placebo in agitation.

Episode 78: A Virtual Reality Platform for Parkison Disease

December 02, 2022

By Matt Hoffman

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Amyloid Copathology Not a Factor in Pharmacodynamic Effect of Irsenontine in Dementia With Lewy Bodies, Parkinson Disease Dementia

December 01, 2022

By Marco Meglio

Over a 12-week treatment period, irsenontrine was well tolerated across both amyloid positive and negative patients, with no significant difference in pharmacodynamic responses or change in central nervous system biomarkers.

Featured


Latest Videos


Most Recent